Health policy versus industrial policy in the pharmaceutical sector: the case of Canada.
This paper analyses the trade-off between health policy and industrial policy objectives in the field of pharmaceuticals in the Canadian policy setting. In Canada pharmaceutical regulation is organized in two tiers. The federal government is responsible for the conduct of industrial policy for the pharmaceutical sector, including the patenting of new molecular entities, the registration and approval of pharmaceutical products, and the pricing of new products. At the province level, policy-makers are responsible for the reimbursement of the cost of medicines; the methodologies implemented for this purpose may be geared towards meeting the objective of cost containment within tight health budgets rather than addressing industrial policy objectives and, thereby, supporting the pharmaceutical industry. The reimbursement methodologies implemented may also be related with the strength of pharmaceutical presence in each province. The paper provides evidence from two such provinces, British Columbia and Ontario, and contrasts pharmaceutical policy-making at the provincial level with that at the federal level.
Vandergrift
M
M
London School of Economics and Political Science, UK. p.g.kanavos@lse.ac.uk
Kanavos
P
P
D001955:British Columbia; D003363:Cost Control; D017277:Drug Approval; D004345:Drug Industry / Q000191:economics / Q000331:legislation & jurisprudence* / Q000592:standards; D017850:Economics, Pharmaceutical / Q000331:legislation & jurisprudence*; D006291:Health Policy; D006801:Humans; D009864:Ontario; D010330:Patents as Topic; D011050:Policy Making